此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Contraceptive Effectiveness of Sino-implant (II) in China

2016年2月16日 更新者:FHI 360

A Study to Evaluate the Contraceptive Effectiveness During the Third, Fourth and Fifth Year of Sino-implant (II) Use and the Pharmacokinetics Over Five Years of Use in Chinese Women

A cohort study to Evaluate the contraceptive effectiveness of Sino-implant (II) during the 3rd and 4th years of use in Chinese women

研究概览

地位

完全的

条件

详细说明

A Study to Evaluate the Contraceptive Effectiveness during the Third, Fourth and Fifth Year of Sino-implant (II)Use and the Pharmacokinetics (PK) over Five Years of use in Chinese Women

Population: A total of 590 Chinese Sino-Implant (II) users between 20and 44 years of age enrolled in one of four prospective cohorts:

Cohort 1: n=20 women with insertion dates 3-5months prior to enrollment and followed for 2-6 months Cohort 2:n=20 women with insertion dates 9-11 months prior to enrollment and followed for 2-6 months Cohort 3: n=250 women with insertion dates 21-24 months prior to enrollment and followed through month 36 Cohort 4:n=300 women with insertion dates 33-36 months prior to enrollment and followed through month 6

Study Duration: 33 total months in the field: 3 months of participant recruitment(all cohorts); up to 27 months of pregnancy monitoring and PK blood sampling in Cohort 4 (up to 15 months in Cohort 3 and 6 months in Cohort 1 and Cohort 2);and 3 months of close-out activities.

For secondary PK outcomes, blood samples will be taken 2 to 6 months apart from each woman in Cohort 1 and Cohort 2; at enrollment, month 30 and month 36 from the first 20 consenting women in Cohort 3; and at enrollment and months 42, 48, 54, and 60 from the first 30 consenting women in Cohort 4.

Primary Objective: To evaluate the contraceptive effectiveness of Sino-implant (II) during the third and fourth years of use

Secondary Objectives:

  1. To evaluate the contraceptive effectiveness of Sino-implant (II) during the fifth year of use.
  2. To characterize the total and free levonorgestrel (LNG) plasma concentration-time profiles over five years following Sino-implant (II) insertion
  3. To characterize the sex hormone binding globulin (SHBG) serum concentration-time profile and its relationship to total LNG levels over five years following Sino-implant (II) insertion

研究类型

观察性的

注册 (实际的)

538

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Anyang、中国
        • An Yang Population and Family Planning Service Station
      • Lingbao、中国
        • Lingbao Population and Family Planning Service
      • Lushi、中国
        • Lushi Family Planning Technical Service Station
      • Shanghai、中国
        • Shanghai Institute of Planned Parenthood
      • Tongxiang、中国
        • Tongxiang Population and Family Planning Service Station

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

20年 至 44年 (成人)

接受健康志愿者

是的

有资格学习的性别

女性

取样方法

非概率样本

研究人群

Study Population: Women who have received contraceptive implants from the Tongxiang, An Yang, Lingbao, and Lushi Family Planning Service Stations.

描述

Inclusion Criteria:

  • Have a confirmed Sino-implant (II) set in place;
  • Have a confirmed contraceptive implant insertion date consistent with the criteria for the cohort she is to be enrolled in;
  • Be aged between 20 and 44 years, inclusive;
  • Not wish to become pregnant in the next year;
  • No desire to get implant removal within the next year;
  • Be able to understand the information given to them and to make personal decisions on whether to participate or not in the study;
  • Consent to participation and sign an informed consent form;
  • Agree and be able to return to the clinic for follow-up visit(s).

Exclusion Criteria:

  • Acute liver disease or cirrhosis by self-report;
  • Benign or malignant tumor of the liver by self-report;
  • Use of rifampicin, and/or anticonvulsants (barbiturates, phenytoin, phenobarbital, carbamazepine, oxcarbazepine, primidone, topiramate), and/or herbal products containing St. John's wort (Hypericum perforatum) by self-report;7
  • Use of medications containing LNG or other hormones that impact LNG or SHBG disposition, e.g. treatment with LNG or oral contraceptives for bleeding disturbances by self-report;
  • Known HIV-positive status by self-report;
  • Any condition (social or medical) which in the opinion of the Investigator would make study participation unsafe, would interfere with adherence to study requirements, or complicate data interpretation.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Cohort 1
n=20 women with insertion dates 3-5months prior to enrollment and followed for 2-6 months
Cohort 2
n=20 women with insertion dates 9-11 months prior to enrollment and followed for 2-6 months
Cohort 3
n=250 women with insertion dates 21-24 months prior to enrollment and followed through month 36
Cohort 4
n=300 women with insertion dates 33-36 months prior to enrollment and followed through month 6

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Pregnancy Pearl Index
大体时间:27 months
Pregnancy Pearl Index (number of pregnancies per 100 woman-years) during the third and fourth years of use, respectively, in Cohort 3 and Cohort 4
27 months

次要结果测量

结果测量
大体时间
Pregnancy Pearl Index during the fifth year of Sino implant (II) use
大体时间:27 months
27 months
Total and free LNG plasma concentrations measured by a high-performance liquid chromatography with mass spectrometry assay
大体时间:27 months
27 months
Serum SHBG concentrations measured by a chemiluminescence immunoassay
大体时间:27 months
27 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Markus Steiner, Ph.D.、FHI 360

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2013年7月1日

初级完成 (实际的)

2015年11月1日

研究完成 (实际的)

2016年1月1日

研究注册日期

首次提交

2013年9月3日

首先提交符合 QC 标准的

2013年9月3日

首次发布 (估计)

2013年9月6日

研究记录更新

最后更新发布 (估计)

2016年2月17日

上次提交的符合 QC 标准的更新

2016年2月16日

最后验证

2016年2月1日

更多信息

与本研究相关的术语

其他研究编号

  • 458241-1

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅